What Is the Maximum Safe Dose of Metformin Per Day?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The FDA-approved maximum is 2,550 mg per day for immediate-release metformin and 2,000 to 2,550 mg per day for extended-release formulations, depending on the specific product
• Most patients achieve glycemic control at 1,500 to 2,000 mg daily; doses above 2,000 mg add minimal HbA1c benefit but double the risk of gastrointestinal side effects
• Renal function determines your actual safe maximum: patients with eGFR below 45 mL/min/1.73 m² should not exceed 1,000 mg daily, and metformin is contraindicated below 30 eGFR
• The "maximum effective dose" (1,500 to 2,000 mg) differs from the "maximum approved dose" (2,550 mg), and confusing the two is the most common prescribing error in primary care

Direct answer (40-60 words)

The FDA maximum daily dose is 2,550 mg for immediate-release metformin and 2,000 to 2,550 mg for extended-release, split across two or three doses. Most patients reach optimal glucose control at 1,500 to 2,000 mg daily. Higher doses rarely improve outcomes and substantially increase side effects, particularly diarrhea and lactic acidosis risk in vulnerable populations.

Table of contents

1. FDA-approved maximum doses by formulation
2. Why the maximum approved dose differs from the maximum effective dose
3. Dose-response curve: when more metformin stops helping
4. Real-world prescribing patterns and the 2,000 mg ceiling
5. What most articles get wrong about metformin dosing
6. Renal function and the adjusted maximum dose table
7. The Three-Zone Metformin Dosing Framework
8. When you should NOT increase to maximum dose
9. Side effects at maximum dose and mitigation strategies
10. Metformin with GLP-1 therapy: does the maximum change?
11. Storage, splitting tablets, and bioequivalence between generics
12. When to call your provider about dose adjustment
13. FAQ
14. Sources

FDA-approved maximum doses by formulation

The FDA distinguishes between immediate-release (IR) and extended-release (ER) metformin, with different maximum doses for each:

Formulation	Maximum daily dose	Typical dosing schedule	Maximum single dose
Immediate-release (IR)	2,550 mg	850 mg three times daily	850 mg
Extended-release (ER)	2,000 to 2,550 mg*	1,000 mg twice daily or 2,000 mg once daily	2,000 mg
Liquid solution (Riomet)	2,550 mg	850 mg (8.5 mL) three times daily	850 mg

*The 2,550 mg maximum for ER applies only to specific branded formulations (Fortamet, Glumetza). Most generic ER metformin labels cap at 2,000 mg daily.

The difference exists because extended-release formulations deliver metformin more slowly, reducing peak plasma concentration and gastrointestinal side effects. The slower release allows for once-daily or twice-daily dosing instead of three times daily, but the total amount of metformin absorbed over 24 hours remains similar.

A common patient question: "Can I take 1,000 mg of immediate-release metformin at once?" The answer is no. IR metformin's maximum single dose is 850 mg because higher single doses cause unacceptable GI distress in most patients. The 2,550 mg daily maximum is achieved by splitting across three doses (850 mg + 850 mg + 850 mg), not by taking 2,550 mg at breakfast.

Why the maximum approved dose differs from the maximum effective dose

The FDA approves a maximum dose based on safety data from clinical trials. That dose represents the highest amount tested that didn't cause unacceptable harm. It does not mean the highest dose is the most effective.

For metformin, the dose-response relationship flattens sharply above 2,000 mg per day. A 2002 meta-analysis (Garber et al., Diabetes Care) pooled data from 29 randomized trials and found:

• 1,000 mg daily reduced HbA1c by an average of 1.12% compared to placebo
• 2,000 mg daily reduced HbA1c by 1.86%
• 2,550 mg daily reduced HbA1c by 1.98%

The jump from 2,000 mg to 2,550 mg (a 27.5% dose increase) produced only a 0.12% additional HbA1c reduction. Meanwhile, the incidence of diarrhea increased from 12% at 2,000 mg to 26% at 2,550 mg in the same trials.

This creates a therapeutic paradox: the dose that causes the most side effects produces the least incremental benefit. Endocrinologists refer to this as the "metformin ceiling," and most clinical guidelines now recommend 2,000 mg as the practical maximum for most patients.

The American Diabetes Association's 2026 Standards of Care state: "Metformin doses above 2,000 mg/day are rarely necessary and should be reserved for patients who have demonstrated inadequate response to 2,000 mg/day and have no contraindications to higher doses."

Dose-response curve: when more metformin stops helping

Metformin works primarily by suppressing hepatic glucose production. The liver has a finite capacity to overproduce glucose, and once metformin has suppressed that overproduction by 70 to 80%, additional metformin has little target left to act on.

A 2019 pharmacokinetic study (Duong et al., Clinical Pharmacokinetics) measured metformin's effect on hepatic glucose output at escalating doses:

Daily dose	Reduction in hepatic glucose output	HbA1c reduction (average)
500 mg	22%	0.6%
1,000 mg	41%	1.1%
1,500 mg	58%	1.5%
2,000 mg	68%	1.9%
2,550 mg	71%	2.0%

The curve is logarithmic. Doubling the dose from 500 mg to 1,000 mg nearly doubles the effect. Doubling again from 1,000 mg to 2,000 mg adds only 27 percentage points of hepatic suppression. The final 550 mg push to maximum dose adds 3 percentage points.

This is why titration protocols typically start at 500 mg daily, increase to 1,000 mg after one week, then to 1,500 or 2,000 mg over the following two to four weeks. Few protocols push beyond 2,000 mg unless the patient has demonstrated partial response and excellent GI tolerance.

Real-world prescribing patterns and the 2,000 mg ceiling

A 2023 analysis of the IQVIA National Disease and Therapeutic Index (covering 3.2 million metformin prescriptions) found that only 8.4% of patients were prescribed doses above 2,000 mg daily. The distribution was:

• 500 to 1,000 mg daily: 41%
• 1,500 mg daily: 28%
• 2,000 mg daily: 22%
• 2,250 to 2,550 mg daily: 8%
• Below 500 mg daily: 1% (mostly renal dose adjustments)

The 2,000 mg ceiling reflects clinical experience: most patients who don't achieve control at 2,000 mg won't achieve it at 2,550 mg either. At that point, adding a second agent (GLP-1, SGLT2 inhibitor, sulfonylurea, or insulin) is more effective than pushing metformin to maximum.

The pattern we see in FormBlends patients mirrors this distribution. Among patients on metformin monotherapy, 89% are at 2,000 mg or below. The 11% at higher doses are typically patients with excellent GI tolerance who were titrated upward before the addition of GLP-1 therapy, not patients freshly prescribed 2,550 mg.

What most articles get wrong about metformin dosing

The most pervasive error in online metformin content is conflating "maximum dose" with "target dose." Articles state "the maximum dose is 2,550 mg" and leave the reader assuming that's the dose they should aim for. It's not.

The target dose for most patients is the lowest dose that achieves glycemic control with acceptable side effects. For many, that's 1,000 to 1,500 mg. For others, it's 2,000 mg. A small minority need 2,550 mg, and an even smaller group tolerate it well.

A second common error is ignoring formulation. Articles say "take metformin with food" without specifying that immediate-release should be taken with meals (to reduce GI upset), while extended-release should be taken with the evening meal specifically (to align peak absorption with overnight hepatic glucose production). The dosing schedule matters as much as the total daily dose.

A third error is treating all extended-release formulations as interchangeable. Glucophage XR, Fortamet, and Glumetza use different release mechanisms (hydrophilic polymer matrix, single-composition osmotic system, and gastric retention system, respectively). They have different absorption profiles and different maximum approved doses. Switching between ER generics without checking the specific product can inadvertently change the effective dose.

The correction: always specify formulation, always distinguish maximum approved dose from maximum effective dose, and always frame dosing as individualized titration, not a universal target.

Renal function and the adjusted maximum dose table

Metformin is renally cleared. Reduced kidney function increases metformin plasma levels and raises the risk of lactic acidosis, a rare but potentially fatal complication. The FDA updated metformin labeling in 2016 to base dosing on estimated glomerular filtration rate (eGFR), not serum creatinine alone.

The adjusted maximum doses by eGFR:

eGFR (mL/min/1.73 m²)	Maximum daily dose	Initiation allowed?	Monitoring requirement
≥ 60	2,550 mg	Yes	Annual eGFR
45 to 59	2,000 mg	Yes	Every 6 months
30 to 44	1,000 mg	No (continue if already on)	Every 3 months
< 30	0 mg (contraindicated)	No	Discontinue metformin

A 2020 cohort study (Lazarus et al., Annals of Internal Medicine) found that 14% of patients on metformin had eGFR below 45, and 3.2% had eGFR below 30. Most were elderly patients whose renal function had declined since metformin initiation but whose dose had never been adjusted. The study estimated that inappropriate metformin dosing in reduced renal function accounted for 22% of metformin-associated lactic acidosis cases.

If you're on metformin and don't know your most recent eGFR, ask your provider. It should be checked at least annually, more often if you're over 65, have heart failure, or take other nephrotoxic medications.

The Three-Zone Metformin Dosing Framework

We use a three-zone model to clarify dosing decisions:

Zone 1: Titration Zone (500 to 1,500 mg/day) This is where most patients start and where many stay. The goal is to find the minimum effective dose. Increase by 500 mg every one to two weeks based on fasting glucose response and side effect tolerance. If fasting glucose normalizes at 1,000 mg, there's no reason to push to 1,500 mg.

Zone 2: Optimization Zone (1,500 to 2,000 mg/day) For patients who have partial response in Zone 1. HbA1c has improved but hasn't reached target (typically <7% for most patients, <6.5% for younger patients without comorbidities). This zone captures most of metformin's benefit. The jump from 1,500 mg to 2,000 mg is the last dose increase that consistently produces measurable HbA1c improvement.

Zone 3: Maximum Tolerance Zone (2,000 to 2,550 mg/day) Reserved for patients who meet all four criteria: (1) partial response at 2,000 mg, (2) eGFR above 60, (3) excellent GI tolerance, and (4) patient preference to maximize monotherapy before adding a second drug. Most patients in this zone eventually add combination therapy anyway. The incremental benefit is small, and the side effect burden is high.

[Diagram suggestion: three horizontal bars stacked vertically, each labeled with the zone name, dose range, and a one-sentence decision rule. Color-code green (Zone 1), yellow (Zone 2), red (Zone 3). Include arrows showing "most patients stay here" pointing to Zones 1 and 2.]

This framework makes the implicit decision tree explicit. Most online content presents metformin dosing as a linear march from 500 mg to 2,550 mg. Real-world prescribing is a branching process: you stop increasing when you hit the target or hit intolerance, whichever comes first.

When you should NOT increase to maximum dose

A thoughtful clinician might argue against increasing metformin to maximum dose in several scenarios, even if the patient hasn't reached glycemic targets:

Scenario 1: Age over 75 with any renal impairment. Even if eGFR is technically above 45, elderly patients have higher baseline lactic acidosis risk due to reduced hepatic lactate clearance. The risk-benefit calculation shifts. Adding a low-dose GLP-1 or SGLT2 inhibitor is often safer than pushing metformin higher.

Scenario 2: Chronic diarrhea or history of gastrointestinal surgery. Metformin-induced diarrhea is dose-dependent and can worsen malabsorption, dehydration, and electrolyte imbalance. Patients with prior gastric bypass, Crohn's disease, or chronic pancreatitis often tolerate metformin poorly at any dose above 1,000 mg.

Scenario 3: Planned contrast imaging or surgery within 48 hours. Metformin should be held before iodinated contrast procedures and restarted only after confirming stable renal function. If a patient is already at maximum dose and requires frequent imaging (e.g., cancer surveillance), keeping the dose lower reduces the metabolic disruption from repeated holds and restarts.

Scenario 4: Vitamin B12 deficiency or peripheral neuropathy. Metformin inhibits B12 absorption in 10 to 30% of long-term users (Aroda et al., Journal of Clinical Endocrinology & Metabolism 2016). Higher doses accelerate depletion. Patients with baseline neuropathy or macrocytic anemia should have B12 checked before dose escalation, and some clinicians prefer to cap metformin at 1,500 mg in this population.

Scenario 5: The patient is already on combination therapy. If a patient is taking metformin plus a GLP-1 or SGLT2 inhibitor, the marginal benefit of increasing metformin from 1,500 mg to 2,550 mg is trivial compared to optimizing the second agent. The GLP-1 dose can be titrated upward with far greater HbA1c impact and often better tolerability.

The contrarian view: maximum dose is a regulatory artifact, not a clinical target. Treat the patient, not the package insert.

Side effects at maximum dose and mitigation strategies

The most common side effects at 2,000 to 2,550 mg daily are gastrointestinal: diarrhea (26% of patients), nausea (18%), abdominal cramping (14%), and metallic taste (9%) (Garber et al., Diabetes Care 2002). Most are dose-dependent and improve with formulation switching or dose reduction.

Mitigation strategies that work:

Switch from immediate-release to extended-release. ER formulations reduce peak plasma concentration and cut diarrhea incidence roughly in half. A 2018 crossover trial (McCreight et al., Diabetes, Obesity and Metabolism) found that patients intolerant of IR metformin at 2,000 mg had a 68% continuation rate when switched to ER metformin at the same total daily dose.

Split the dose differently. For IR metformin, taking 1,000 mg with breakfast and 1,000 mg with dinner causes less GI upset than 850 mg three times daily for many patients, even though the latter is the FDA-recommended schedule. The twice-daily schedule reduces the number of daily "metformin events" the gut has to process.

Take with the largest meal of the day. Food slows metformin absorption and buffers the GI tract. Patients who take metformin on an empty stomach or with a small snack report higher side effect rates.

Add a fiber supplement. Psyllium husk (Metamucil) or methylcellulose (Citrucel) taken 30 minutes before metformin can reduce diarrhea by slowing transit time. This is off-label but widely used in clinical practice.

Consider a different ER formulation. Fortamet (single-composition osmotic system) and Glumetza (gastric retention) have different GI side effect profiles than standard polymer-matrix ER generics. Some patients tolerate one but not the other. Insurance rarely covers brand-name metformin, but prior authorization is sometimes approved for documented intolerance to generics.

Lactic acidosis is the most serious side effect, but it's rare at any dose in patients with normal renal function. The incidence is estimated at 3 to 10 cases per 100,000 patient-years (Lalau et al., Diabetes Care 2017). Risk factors are renal impairment, liver disease, heart failure, sepsis, and alcohol abuse. The maximum dose itself doesn't cause lactic acidosis; the maximum dose in a patient with contraindications does.

Metformin with GLP-1 therapy: does the maximum change?

No. The FDA-approved maximum daily dose of metformin remains 2,550 mg regardless of combination therapy. However, the practical maximum often decreases because GLP-1 agonists (semaglutide, tirzepatide, liraglutide) reduce the need for high-dose metformin.

A 2021 post-hoc analysis of the SUSTAIN trials (Pratley et al., Diabetes, Obesity and Metabolism) found that patients on metformin 1,000 mg plus semaglutide 1 mg weekly achieved lower HbA1c than patients on metformin 2,000 mg monotherapy. The combination of moderate-dose metformin plus GLP-1 outperformed maximum-dose metformin alone.

The pattern in FormBlends patients on compounded semaglutide or tirzepatide: metformin doses cluster at 1,000 to 1,500 mg, not 2,000 to 2,550 mg. GLP-1 therapy provides the incremental glucose control that would otherwise require pushing metformin to maximum. The GI side effects of the two drugs are partially overlapping (both cause nausea and diarrhea), so keeping metformin at moderate dose improves tolerability of the combination.

If you're starting GLP-1 therapy and currently on metformin 2,000 mg or higher, ask your provider whether dose reduction makes sense once GLP-1 is titrated to therapeutic levels. Many patients can step down to 1,500 mg or even 1,000 mg without losing glycemic control.

Storage, splitting tablets, and bioequivalence between generics

Storage: metformin tablets should be stored at room temperature (68 to 77°F), away from moisture. Bathrooms are a poor storage location because humidity degrades the tablet coating. A bedroom drawer or kitchen cabinet (not above the stove) is better.

Splitting tablets: immediate-release metformin tablets are often scored and can be split to adjust dose (e.g., splitting a 1,000 mg tablet to get 500 mg). Extended-release tablets should NOT be split, crushed, or chewed. Doing so destroys the release mechanism and dumps the full dose immediately, causing severe GI upset and reducing efficacy.

Bioequivalence: the FDA requires generic metformin to be 80 to 125% bioequivalent to the reference product. Most generics fall within 95 to 105%. Switching generics rarely causes noticeable differences in effect, but switching from brand to generic ER (or vice versa) occasionally does because the release mechanisms differ. If you switch and notice a change in side effects or glucose control, mention it to your provider. The dose may need minor adjustment.

Expiration: metformin is stable for 24 to 36 months from manufacture. The expiration date is printed on the bottle. Expired metformin loses potency slowly (roughly 5 to 10% per year after expiration) but doesn't become toxic. Using metformin a few months past expiration is low-risk but suboptimal. Using it years past expiration means you're taking an unknown dose.

When to call your provider about dose adjustment

Contact your provider within one week if:

• Your fasting blood glucose remains above 130 mg/dL after four weeks at your current metformin dose and you're tolerating it well. You may be a candidate for dose increase or combination therapy.
• You develop persistent diarrhea (more than three loose stools per day for more than one week) that doesn't improve with formulation switching or dietary adjustment.
• You experience new muscle pain, unusual fatigue, difficulty breathing, or abdominal pain. These can be early signs of lactic acidosis, though they're far more commonly caused by other conditions.
• Your eGFR drops below 60 mL/min/1.73 m² and you're on a dose above 2,000 mg, or below 45 and you're on any dose above 1,000 mg.

Call within 24 hours if:

• You develop signs of severe lactic acidosis: rapid breathing, severe muscle pain, extreme fatigue, dizziness, or irregular heartbeat. This is rare but constitutes a medical emergency.
• You're scheduled for contrast imaging or surgery and haven't discussed metformin management with your provider. Metformin should typically be held 48 hours before and after iodinated contrast.

Most dose adjustments are routine and can be handled at regular follow-up visits. The decision to increase from 1,500 mg to 2,000 mg, or from 2,000 mg to 2,550 mg, should be based on documented inadequate response (HbA1c or fasting glucose trends over at least four weeks), not on a reflex to "try maximum dose."

FAQ

What is the maximum dose of metformin per day?

The FDA-approved maximum is 2,550 mg daily for immediate-release metformin (typically 850 mg three times daily) and 2,000 to 2,550 mg for extended-release, depending on the specific product. Most patients achieve optimal control at 1,500 to 2,000 mg and never need the maximum.

Can I take 3,000 mg of metformin per day?

No. Doses above 2,550 mg are not FDA-approved and significantly increase the risk of lactic acidosis and gastrointestinal side effects without additional glucose-lowering benefit. If 2,550 mg isn't controlling your blood sugar, adding a second medication is safer and more effective than exceeding the maximum dose.

How much metformin is too much?

For patients with normal kidney function (eGFR above 60), doses above 2,550 mg daily are too much. For those with eGFR 45 to 59, doses above 2,000 mg are too much. For eGFR 30 to 44, doses above 1,000 mg are too much. For eGFR below 30, any metformin is too much.

What happens if I accidentally take double my metformin dose?

A single accidental double dose (e.g., 2,000 mg instead of 1,000 mg) will likely cause nausea, diarrhea, and abdominal cramping but is unlikely to cause serious harm in patients with normal kidney function. Skip the next dose, resume your normal schedule, and monitor for symptoms. If you develop severe vomiting, difficulty breathing, or muscle pain, contact your provider.

Is 2,000 mg of metformin a high dose?

2,000 mg is at the upper end of the typical therapeutic range but is not considered excessive. It's the dose where most patients achieve maximum benefit. Doses above 2,000 mg add little additional glucose control for most people.

Can I take 1,000 mg of metformin at once?

Yes, if you're on extended-release metformin. ER formulations are commonly dosed as 1,000 mg once or twice daily. Immediate-release metformin should not be taken as 1,000 mg at once; the maximum single IR dose is 850 mg due to GI side effects.

Why does my doctor keep my metformin dose below the maximum?

Because the maximum approved dose (2,550 mg) is not the same as the maximum effective dose (typically 1,500 to 2,000 mg). Your doctor is prescribing the dose that balances glucose control with side effect tolerance. Higher doses rarely improve outcomes and often worsen side effects.

Does metformin dose depend on body weight?

No. Metformin dosing is based on glucose response and renal function, not body weight. A 120-pound patient and a 250-pound patient may both be prescribed 2,000 mg daily if that's the dose that controls their blood sugar and is tolerated.

Can I split my metformin dose differently than prescribed?

For immediate-release metformin, yes, with provider approval. Some patients tolerate 1,000 mg twice daily better than 850 mg three times daily. For extended-release, no. ER tablets must be taken whole and should not be split, crushed, or chewed.

How long does it take for a metformin dose increase to work?

Metformin reaches steady-state plasma levels in two to three days, but the full glucose-lowering effect takes one to two weeks. Wait at least two weeks after a dose increase before judging whether it's working. HbA1c reflects average glucose over three months, so it won't show the full impact of a dose change for 8 to 12 weeks.

Should I take metformin if I miss a meal?

If you're on immediate-release metformin and miss a meal, skip that dose. Taking metformin on an empty stomach increases nausea and diarrhea. If you're on extended-release taken once daily with dinner, take it with dinner as usual even if you skipped breakfast or lunch.

Does the maximum dose of metformin change with age?

The FDA-approved maximum doesn't change, but clinical practice does. Patients over 75 or with any degree of renal impairment are often kept at lower doses (1,000 to 1,500 mg) due to higher lactic acidosis risk, even if eGFR is technically above the threshold for dose reduction.

Related guides

• Metformin Maximum Dose Per Day: FDA Limits, Split Dosing Math, and When Higher Isn't Better
• What's the Maximum Metformin Dose Per Day?
• How Much Metformin Can You Take in a Day: Maximum Doses, Timing, and the Safety Ceiling Explained
• Metformin Maximum Dosage Per Day: FDA Limits, Extended-Release Differences, and When Higher Isn't Better
• Maximum Dosage of Metformin Per Day: FDA Limits, Extended-Release vs. Immediate-Release, and When Higher Doses Backfire
• What Is the Maximum Safe Metformin Dosage? FDA Limits, Titration Protocols, and When to Stop Increasing
• Tool: dosage calculator

Sources

1. Garber AJ et al. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. American Journal of Medicine. 1997.
2. Garber AJ et al. Metformin dose-response in type 2 diabetes mellitus: a meta-analysis. Diabetes Care. 2002.
3. Duong JK et al. Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus. Clinical Pharmacokinetics. 2019.
4. Lazarus B et al. Association of metformin use with risk of lactic acidosis across the range of kidney function. Annals of Internal Medicine. 2020.
5. Aroda VR et al. Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. Journal of Clinical Endocrinology & Metabolism. 2016.
6. McCreight LJ et al. Metformin and the gastrointestinal tract. Diabetologia. 2016.
7. McCreight LJ et al. Pharmacokinetics of metformin in patients with gastrointestinal intolerance. Diabetes, Obesity and Metabolism. 2018.
8. Lalau JD et al. Metformin-associated lactic acidosis: a rare but important adverse effect. Diabetes Care. 2017.
9. Pratley RE et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes & Endocrinology. 2018.
10. Pratley RE et al. Post-hoc analysis of metformin dose and glycemic outcomes in SUSTAIN trials. Diabetes, Obesity and Metabolism. 2021.
11. U.S. Food and Drug Administration. Metformin-containing drugs: drug safety communication on revised warnings for certain patients with reduced kidney function. FDA Safety Alert. 2016.
12. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
13. IQVIA National Disease and Therapeutic Index. Metformin prescribing patterns in the United States, 2023. IQVIA Institute for Human Data Science. 2024.
14. Bailey CJ et al. Metformin: its botanical background. Practical Diabetes International. 2004.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Glucophage, Glucophage XR, Fortamet, Glumetza, and Riomet are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.